US Venture Partners — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
San Mateo, US
Nicholas Woodman(Executive Officer, Director)Brian McGee(Executive Officer)
BoardEmily Culp-Hogue(Director)Miguel A. Lopez Ben(Director)Tyrone Ahmad-Taylor(Director)Michael Dennison(Director)
Co-investorsEnerdigm Ventures
Cagent Vascular develops endovascular medical devices, including the Serranator PTA Serration Balloon Catheter, for the treatment of vascular disease.
HardwareHealthtechMedical DevicesWayne, US
Brian Walsh(Chairman & CEO)inPeter Johansson(Chief Quality & Compliance Officer, VP Engineering)Paul Wilson(Chief Commercial Officer)Matt Condron(SVP of Operations)Corey Latanision(SVP of Marketing & International Sales)Peter Schneider(Chief Medical Advisor, Co-Founder)
Board seatCasey Tansey· per SEC Form D
Co-investorsAstoria Health InvestorsU.S. Venture Partners
New York, US
Teodor P. Grantcharov(Executive Officer, Director)
BoardPeter Charbonneau(Director)Dennis McWilliams(Director)Hartley Stern(Director)
Board seatJonathan RootDafina Toncheva· per SEC Form D · $20.2M raise · filed Mar 2026
Maneva develops Video-to-Action AI for manufacturers, converting production-floor visual data into real-time actions for quality control, machine integrity, and line supervision (via its ALIS AI Line Supervisor).
Advanced ManufacturingAI & Machine LearningRoboticsToronto
Rae Chan Jeong(Executive Officer, Director)Rae Jeong(Co-Founder & CEO)inKelvin Chan(Co-Founder & CTO)
Co-investors640 OxfordArka Venture LabsBling CapitalEvolution VC PartnersN49PFreestyle Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.